Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
Auteurs : Albisinni S, Martinez Chanza N, Aoun F, Diamand R, Mjaess G, Azzo JM, Esperto F, Bellmunt J, Roumeguère T, DE Nunzio C Jaar : 2021 Journal : Minerva Urol Nephrol
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ Jaar : 2021 Journal : Prostate Cancer Prostatic Dis
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
Auteurs : Epaillard N, Parent P, Loriot Y, Lavaud P, Vera-Cea EB, Martinez Chanza N, Rodriguez-Vida A, Dumont C, Lozano R, Llácer C, Ratta R, Oudard S, Thibault C, Auclin E Jaar : 2021 Journal : Front Oncol
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
Auteurs : Zambrana F, Carril-Ajuria L, Gómez de Liaño A, Martinez Chanza N, Manneh R, Castellano D, de Velasco G Jaar : 2021 Journal : Cancer Treat Rev
Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.
Auteurs : Thouvenin J, Martinez Chanza N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG Jaar : 2021 Journal : Cancers (Basel)